Biolife solutions expands intellectual property estate

7 new granted patents; 43 submitted patent applications global portfolio now totals 148 issued and 114 pending patents bothell, wash. , nov. 21, 2022 /prnewswire/ -- biolife solutions, inc. (nasdaq: blfs) ("biolife" or the "company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (cgt) and the broader biopharma markets, today provided an update on the expansion of its intellectual property estate.
BLFS Ratings Summary
BLFS Quant Ranking